175 Never mind that Health Net was right: E. A.
Stadtmauer, A. O’Neill, L. J. Goldstein et al.,
“Conventional-Dose Chemotherapy Compared with
High-Dose Chemotherapy plus Autologous
HematopoieticStem-CellTransplantationforMetastatic
BreastCancer,”NewEnglandJournalof Medicine 342
(2000): 1069–76. See also Rettig et al.,False Hope.
175 Aetna,decided to try a different approach: R.
Krakaueretal.,“OpportunitiestoImprovetheQualityof
Care for AdvancedIllness,” HealthAffairs 28 (2009):
1357–59.
176 A two-year study of this “concurrent care”
program:C.M.Spettelletal.,“AComprehensiveCase
Management Program to Improve Palliative Care,”
Journal ofPalliativeMedicine 12 (2009):827–32. See
also Krakauer et al. “Opportunities to Improve.”
176 Aetna ran a more modest concurrent care
program: Spettel et al., “A Comprehensive Case
Management Program.”
177 Two-thirds of the terminal cancer patients:
Wright et al., “Associations Between End-of-Life
Discussions.”
177 Alandmark 2010 studyfromtheMassachusetts
General Hospital: J. S. Temel et al.,“Early Palliative
CareforPatientswithMetastaticNon-SmallCellLung
Cancer,”NewEnglandJournalofMedicine 363 (2010):
733–42;J.A.Greeretal.,“EffectofEarlyPalliativeCare
onChemotherapyUseandEnd-of-LifeCareinPatients
withMetastaticNon-SmallCellLungCancer,” Journal
of Clinical Oncology30 (2012): 394–400.